205 -2 (88) 2026 - M.Zh. Sanoyeva - MULTIPLE SCLEROSIS IN PREGNANT WOMEN – CLINICAL COURSE AND MANAGEMENT

MULTIPLE SCLEROSIS IN PREGNANT WOMEN – CLINICAL COURSE AND MANAGEMENT

M.Zh. Sanoyeva - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

A historical review of multiple sclerosis (MS) showed that women with MS were previously discouraged from having children. Since the late 1990s, clinical studies have demonstrated a reduction in relapse activity during pregnancy, especially in the third trimester, with an increase postpartum. Women with MS are concerned about potential adverse effects on pregnancy and childbirth. This article provides a concise overview of the literature and current recommendations for the management of pregnant women with MS, including family planning, delivery, and breastfeeding.

Keywords: multiple sclerosis, pregnancy, exacerbation, clinical course, therapeutic management.

First page

1127

Last page

1134

For citation:M.Zh. Sanoyeva - MULTIPLE SCLEROSIS IN PREGNANT WOMEN – CLINICAL COURSE AND MANAGEMENT//New Day in Medicine 2(88)2026 1127-1134 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

  1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17:162–73.
  2. Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology. 2018;90(22):e1954–e63.
  3. Houtchens MK, Edwards NC, Phillips AL. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology. 2018;91(17):e1570–e8.
  4. Bsteh G, Algrang L, Hegen H, Auer M, Wurth S, Di Pauli F, et al. Pregnancy and multiple sclerosis in the DMT era: a cohort study in Western Austria. Mult Scler. 2020; 26:69–78.
  5. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285–91.
  6. Langer-Gould A, Smith JB, Albers KB, Xiang AH, Wu J, Kerezsi EH, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020;94(18):1–e11.
  7. Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, et al. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology. 2019;92(13):e1507–16.
  8. De Angelis F, John NA, Brownlee WJ. Diseasemodifying therapies for multiple sclerosis. BMJ. 2018; 363:4674.
  9. Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology. 2018;90(10):e840–6.
  10. Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Mult Scler Relat Disord. 2019;28:235–43. European Medicines Agency (EMA). Evaluation of medicines for human use. Guidelines on risk assessment of medical products on human reproduction and lactation: from data to labeling [Internet]. London: EMA; 2008 [cited 2020 Jan 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003307.pdf

    file

    download